InvivoChem Cat #:V7461CAS #:934240-31-0Purity >=98%Description: Raxatrigine(also known as GSK-1014802 and CNV-1014802) is a novel, potent smallmolecule state-dependent sodium channel blocker, the Nav1.7 sodiumchannel inhibitor. It has the potential to be used as an analgesic andis being developed by Convergence Pharmaceuticals for the treatment oflumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).
Raxatrigine(also known as GSK-1014802 and CNV-1014802) is a novel, potent smallmolecule state-dependent sodium channel blocker, the Nav1.7 sodiumchannel inhibitor. It has the potential to be used as an analgesic andis being developed by Convergence Pharmaceuticals for the treatment oflumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). References: Theefficacy of sodium channel blockers to prevent phencyclidine-inducedcognitive dysfunction in the rat: potential for novel treatments forschizophrenia. J Pharmacol Exp Ther. 2011 Jul; 338(1):100-13.; Deuis JR, Wingerd JS, Winter Z, Durek T, Dekan Z, Sousa SR, Zimmermann K, Hoffmann T, Weidner C, Nassar MA, Alewood PF, Lewis RJ, Vetter I. AnalgesicEffects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-MediatedPain. Toxins (Basel). 2016 Mar 17; 8(3). pii: E78.
Related CAS #: 934240-31-0 (HCl) 934240-30-9 (free base) 934240-35-4 (mesylate)